AR004675A1 - Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas. - Google Patents
Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.Info
- Publication number
- AR004675A1 AR004675A1 ARP960103850A AR10385096A AR004675A1 AR 004675 A1 AR004675 A1 AR 004675A1 AR P960103850 A ARP960103850 A AR P960103850A AR 10385096 A AR10385096 A AR 10385096A AR 004675 A1 AR004675 A1 AR 004675A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparing
- pharmaceutical compositions
- procedure
- compounds
- cor6
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- -1 1H-tetrazol-5-yl Chemical group 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Nuevos compuestos antagonistas de receptores de endotelina de fórmula (I), en la que -Y-Z- es -NR7-CO,-N=C(OR79- ó N-CR8-; R1 es -NR7-CO, -N=C(OR7)-,-N=C(OR7)- ó -N=CR8; R1 es Ar; R2 es COR6, (CH2)nCOOR6, CN, 1H-tetrazol-5-ilo ó CONHSO2Ar; R1,R4,R5 independientemente representan R6, OR6, S(O)mR6, Hal,NO2, NR6R6, NHCOR6, NHSO2R6, OCOR6, COR6 ó CN, donde R1 y R4 pueden representar, en conjunto, también un grupo O(CH2)nO; R6, R6 independientementeson H, alquilo de 1 a 6 átomos decarb ono, bencilo o fenilo, R7 es (CH2nAr, R8 es Ar ó OAr; Ar es un fenilo no sustituido o sustituido una, dos o tres vecescon R9, R10 ó R11 o un naftilo no sustituido o un grupo (II) no sustituido o sustituido una o dos veces el fenilo con R9 óR10 ó un grupo (III) nosustituido o sustituido una o dos veces en el ciclohexadienilo con R9 ó R10; R9, R10, R11 independientemente son R6, OR6, Hal, CF3, OCF3, OCHF2, OCH2F, NO2,NR6R6, NHCOR6, CN, NHSO2R6, COOR6, COR6, CONHSO2Ar, O(CH2)NR2,O(CH2)NOR6 ó S8o)nR6; E es CH2, S ú O, D es carbonilo ó [C(R6R6)]n, Hal es F, Cl, Br ó I; Xes O ó S;m es 0, 1 ó 2;n es 1 ó 2; y las sales de estos compuestos. También se refiere a unprocedimiento para preparar dichos compuestos, acomposicionesfarmacéutica s que los contienen, y a un procedimiento para la elaboración de dichas composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19528418A DE19528418A1 (de) | 1995-08-02 | 1995-08-02 | Endothelin-Rezeptor-Antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004675A1 true AR004675A1 (es) | 1999-03-10 |
Family
ID=7768528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103850A AR004675A1 (es) | 1995-08-02 | 1996-08-02 | Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5731321A (es) |
| EP (1) | EP0757039A1 (es) |
| JP (1) | JPH0940649A (es) |
| KR (1) | KR970010746A (es) |
| AR (1) | AR004675A1 (es) |
| AU (1) | AU705959B2 (es) |
| BR (1) | BR9603252A (es) |
| CA (1) | CA2182469A1 (es) |
| CZ (1) | CZ224096A3 (es) |
| DE (1) | DE19528418A1 (es) |
| HU (1) | HUP9602127A1 (es) |
| MX (1) | MX9603199A (es) |
| NO (1) | NO963213L (es) |
| PL (1) | PL315479A1 (es) |
| SK (1) | SK100296A3 (es) |
| ZA (1) | ZA966552B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251861B1 (en) * | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| US7825131B2 (en) * | 2003-09-23 | 2010-11-02 | Merck Sharp & Dohme Corp. | Quinoline potassium channel inhibitors |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| JP5634263B2 (ja) * | 2007-08-16 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナゾリンジオンキマーゼ阻害剤 |
| ATE541841T1 (de) * | 2007-11-15 | 2012-02-15 | Boehringer Ingelheim Int | Inhibitoren der replikation des human immunodeficiency virus |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| GB9115153D0 (en) * | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
| DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
| US5565472A (en) * | 1992-12-21 | 1996-10-15 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents |
| ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| DE69422742T2 (de) * | 1993-03-19 | 2000-08-17 | Merck & Co., Inc. | Phenoxyphenylessigsäurederivate |
| JPH06340658A (ja) * | 1993-04-08 | 1994-12-13 | Kyowa Hakko Kogyo Co Ltd | ベンゾイミダゾール誘導体 |
| US5817653A (en) * | 1993-08-06 | 1998-10-06 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| DE4341663A1 (de) * | 1993-12-07 | 1995-06-08 | Basf Ag | Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung |
-
1995
- 1995-08-02 DE DE19528418A patent/DE19528418A1/de not_active Withdrawn
-
1996
- 1996-07-29 AU AU60792/96A patent/AU705959B2/en not_active Ceased
- 1996-07-29 CZ CZ962240A patent/CZ224096A3/cs unknown
- 1996-07-31 CA CA002182469A patent/CA2182469A1/en not_active Abandoned
- 1996-07-31 EP EP96112347A patent/EP0757039A1/de not_active Withdrawn
- 1996-07-31 SK SK1002-96A patent/SK100296A3/sk unknown
- 1996-08-01 ZA ZA9606552A patent/ZA966552B/xx unknown
- 1996-08-01 NO NO963213A patent/NO963213L/no unknown
- 1996-08-01 BR BR9603252A patent/BR9603252A/pt not_active Application Discontinuation
- 1996-08-01 KR KR1019960032224A patent/KR970010746A/ko not_active Withdrawn
- 1996-08-01 PL PL96315479A patent/PL315479A1/xx unknown
- 1996-08-01 US US08/691,148 patent/US5731321A/en not_active Expired - Fee Related
- 1996-08-01 HU HU9602127A patent/HUP9602127A1/hu unknown
- 1996-08-02 JP JP8219113A patent/JPH0940649A/ja active Pending
- 1996-08-02 MX MX9603199A patent/MX9603199A/es unknown
- 1996-08-02 AR ARP960103850A patent/AR004675A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9603199A (es) | 1997-07-31 |
| BR9603252A (pt) | 1998-04-28 |
| AU6079296A (en) | 1997-02-06 |
| HUP9602127A1 (hu) | 1998-05-28 |
| CA2182469A1 (en) | 1997-02-03 |
| JPH0940649A (ja) | 1997-02-10 |
| KR970010746A (ko) | 1997-03-27 |
| US5731321A (en) | 1998-03-24 |
| NO963213D0 (no) | 1996-08-01 |
| ZA966552B (en) | 1997-02-18 |
| AU705959B2 (en) | 1999-06-03 |
| HU9602127D0 (en) | 1996-09-30 |
| DE19528418A1 (de) | 1997-02-06 |
| EP0757039A1 (de) | 1997-02-05 |
| NO963213L (no) | 1997-02-03 |
| PL315479A1 (en) | 1997-02-03 |
| CZ224096A3 (en) | 1997-02-12 |
| SK100296A3 (en) | 1997-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ511739A (en) | New esters derived from substituted phenyl-cyclohexyl compounds | |
| AR033306A1 (es) | Compuestos | |
| AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| PT96890A (pt) | Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem | |
| CO5021213A1 (es) | INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8 | |
| FI961300A0 (fi) | Hydroksisubstituoituja atsetidinoniyhdisteitä, jotka ovat käyttökelpoisia hypokolesterolemisia yhdisteitä | |
| ECSP034660A (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| CO4440627A1 (es) | Antagonistas de factor de liberacion de corticotropina | |
| CO4950564A1 (es) | Nuevo proceso para la preparacion de una sustancia farmaco- logimante activa | |
| CO5690588A2 (es) | Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor | |
| ATE369855T1 (de) | Modulatoren von peroxisome proliferator- aktivierten rezeptoren | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| ES2100907T3 (es) | Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion. | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| CO5280081A1 (es) | Antibacterianos de piperidiniloxi oxazolidinona, composicion farmaceutica que los comprende y proceso para su preparacion | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| CO5200758A1 (es) | Derivados de 1,5-dihidropirrol-2-ona sustituida, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos | |
| AR004675A1 (es) | Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas. | |
| AR010809A1 (es) | Compuestos derivados de aminofosfonatos, un procedimiento para su preparacion, composicion farmaceutica que los comprenden, uso de los mismospara la fabricacion de un medicamento util en el tratamiento de arterioesclerosis | |
| PE20001339A1 (es) | Uso de derivados del acido 4-biarilbutirico y 5-biarilpentanoico sustituidos como inhibidores de la metaloproteasa de matriz para el tratamiento de enfermedades respiratorias | |
| PE27497A1 (es) | Derivados de 1,5 benzodiazepina | |
| UY28688A1 (es) | Derivados de amida | |
| CO5190692A1 (es) | Derivados de pirrolidin-2,3,4-trion-3-oxima sustituida, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos | |
| AR023111A1 (es) | Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden |